Five year outcome of lentiviral gene therapy for human beta-thalassemia, lessons and prospects

Philippe Leboulch

Institute of Emerging Diseases and Innovative Therapies, INSERM U. 962, University Paris 11
Bluebird bio, France and Harvard Medical School, Brigham and Women’s Hospital, Boston, MA

Oral presentation
Oral presentation is available online